These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 19188038)

  • 21. Comparison of the enthalpy recovery and free volume of polyvinylpyrrolidone during anomalous glassy to rubbery transition.
    Zelkó R; Süvegh K
    Eur J Pharm Sci; 2004 Mar; 21(4):519-23. PubMed ID: 14998583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of dynamic neural networks in the modeling of drug release from polyethylene oxide matrix tablets.
    Petrović J; Ibrić S; Betz G; Parojcić J; Durić Z
    Eur J Pharm Sci; 2009 Sep; 38(2):172-80. PubMed ID: 19632323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Dissolution rate and bioavailability of famotidine tablets].
    Lu B; He YJ; Guo P; Ye LM
    Yao Xue Xue Bao; 1992; 27(4):303-7. PubMed ID: 1442047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug release profiles and microstructural characterization of cast and freeze dried vitamin B12 buccal films by positron annihilation lifetime spectroscopy.
    Szabó B; Kállai N; Tóth G; Hetényi G; Zelkó R
    J Pharm Biomed Anal; 2014 Feb; 89():83-7. PubMed ID: 24269613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stability of metronidazole, tetracycline HCl and famotidine alone and in combination.
    Wu Y; Fassihi R
    Int J Pharm; 2005 Feb; 290(1-2):1-13. PubMed ID: 15664125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Compatibility studies of promethazine hydrochloride with tablet excipients by means of thermal and non-thermal methods.
    Thumma S; Repka MA
    Pharmazie; 2009 Mar; 64(3):183-9. PubMed ID: 19348341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potentiometric determination of famotidine in pharmaceutical formulations.
    Ayad MM; Shalaby A; Abdellatef HE; Elsaid HM
    J Pharm Biomed Anal; 2002 Jun; 29(1-2):247-54. PubMed ID: 12062684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Liquid chromatography in pharmaceutical analysis: determination in tablets of famotidine, a new H2-antagonists].
    Ficarra R; Ficarra P; Calabrò ML
    Farmaco Prat; 1987 Nov; 42(11):307-12. PubMed ID: 2893743
    [No Abstract]   [Full Text] [Related]  

  • 29. Quantitative determination of famotidine through charge-transfer complexation with chloranilic acid.
    Chukwurah BK; Ajali U
    Boll Chim Farm; 2001; 140(5):354-60. PubMed ID: 11680091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preparation and evaluation of famotidine polymorphs.
    Nagaraju R; Prathusha AP; Subhash Chandra Bose P; Kaza R; Bharathi K
    Curr Drug Discov Technol; 2010 Jun; 7(2):106-16. PubMed ID: 20836758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection of moisture-sensitive drugs with aqueous polymer coatings: importance of coating and curing conditions.
    Bley O; Siepmann J; Bodmeier R
    Int J Pharm; 2009 Aug; 378(1-2):59-65. PubMed ID: 19477253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simultaneous probing of swelling, erosion and dissolution by NMR-microimaging--effect of solubility of additives on HPMC matrix tablets.
    Tajarobi F; Abrahmsén-Alami S; Carlsson AS; Larsson A
    Eur J Pharm Sci; 2009 May; 37(2):89-97. PubMed ID: 19429415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of chemical heterogeneity of HPMC on polymer release from matrix tablets.
    Viridén A; Wittgren B; Andersson T; Larsson A
    Eur J Pharm Sci; 2009 Mar; 36(4-5):392-400. PubMed ID: 19049865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and biopharmaceutical evaluation of extended release formulation of tramadol hydrochloride based on osmotic technology.
    Kumar P; Singh S; Mishra B
    Acta Pharm; 2009 Mar; 59(1):15-30. PubMed ID: 19304555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preformulation experiences and in vitro model studies with spironolactone-containing suppositories.
    Regdon G; Deák D; Regdon G; Muskó Z; Erös I
    Pharmazie; 2001 Jan; 56(1):70-3. PubMed ID: 11213791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of a novel symmetrical shape factor to gastroretentive matrices as a measure of swelling synchronization and its impact on drug release kinetics under standard and modified dissolution conditions.
    Liu Q; Fassihi R
    J Pharm Pharmacol; 2009 Jul; 61(7):861-7. PubMed ID: 19589227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extractional-spectrophotometric determination of famotidine in pharmaceutical formulations.
    Abu Zuhri AZ; Shubietah RM; Badah GM
    J Pharm Biomed Anal; 1999 Nov; 21(2):459-65. PubMed ID: 10704003
    [No Abstract]   [Full Text] [Related]  

  • 38. [Pphysical ageing of amorphous polymeric excipients II. Tracking possibilities].
    Zelkó R; Kiss D
    Acta Pharm Hung; 2006; 76(1):55-63. PubMed ID: 17094676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Use of galactomannan to produce hydrophilic matrix tablets].
    Berta E; Hódi K; Révész P; Miseta M; Selmeczi B
    Acta Pharm Hung; 1994 Jan; 64(1):26-9. PubMed ID: 8023683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The effect of physical aging on the structural behavior of amorphous poly(vinylpyrrolidone) polymers].
    Zelkó R; Süvegh K
    Acta Pharm Hung; 2003; 73(1):46-50. PubMed ID: 12891899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.